OraSure faces more delays for oral hepatitis C test
This article was originally published in Clinica
Executive Summary
US approval of the oral fluid version of OraSure Technologies’ OraQuick hepatitis C virus (HCV) test looks likely to be delayed again, after the FDA questioned its sensitivity.